Why:
- The growth on the cover is not the growth underneath. Reported revenue rose 24.7% in FY2026, but the factory's own products grew 12.2%; the rest was bought-in goods resold at a 1.5% margin (T1). The original plant actually produced 5.5% less than the year before, and exports, the part of the business the company leads with, fell 1% (T1).
- The money being raised triples capacity into a market that cannot take it. The ₹108 crore expansion lifts nameplate capacity to 1,15,344 tonnes a year. On the filing's own market numbers, that is more than half of all Indian demand for these products, so the plan only works as an export bet (T3). Exports shrank last year, India's whole export trade in these chemicals is about ₹189 crore a year, and a new African plant is being built to serve the same buyers from 2027 (T3).
- Governance moved the wrong way just before filing. The two promoters' pay ceiling was raised from ₹94 lakh drawn to ₹3.6 crore a year, payable even in loss years, one month before the RHP, and their bank agreements require written consent for that which the filing does not show (T1). The food-safety registration for a business that earns 36% of revenue from food and beverage customers was rejected, with a fresh application pending (T1).
Valuation at the band
| Floor ₹79 (T1) | Cap ₹83 (T1) | |
|---|---|---|
| Bid window | 31 Aug to 2 Sep 2026 | |
| Bid lot | 1,600 shares | |
| Post-issue shares | 1,72,47,400 | 1,72,47,400 |
| Market capitalisation | ₹136 cr | ₹143 cr |
| P/E on FY2026 profit | 13.3x | 14.0x |
| P/E excluding the FY2026 currency gain | 14.4x | 15.1x |
| EV/EBITDA (reported net debt) | 10.8x | 11.3x |
| Promoter holding after | 50.15% | 50.15% |
The filing names no comparable listed company, so it offers no peer multiple to compare these against. The price does not move the verdict.
The story
You are buying a small, profitable Gujarat chemicals plant that is full, and a bet that a new plant three times the size can be filled. The one new plant the company has already built has run at 15% of capacity for a year and a half.
What this business is
Shanti Inorganics buys liquefied sulphur dioxide and reacts it with soda ash, caustic soda or ammonia to make four sulphite salts. These are sold as food preservatives, water-treatment chemicals and industrial reducing agents to 64 Indian customers and 20 export customers across 11 countries. Revenue in FY2026 was ₹71 crore, profit ₹10 crore.
The original plant at Vatva, Ahmedabad has run above 92% of capacity for three years. A second site at Bavla added an 18,000-tonne line for a new product, sodium sulphite, in February 2025; it ran at 15% in its first full year, partly because its operating consents and boiler certificate arrived up to a year after production began. The IPO part-funds a much larger Phase II at Bavla, making the same products as the full Vatva plant.
Easy or difficult business? Run-of-the-mill chemistry. The reactions are single-step, there are no patents, and the company's own filing says competition is on price and quality. The genuine difficulties are hazardous-materials handling, food-grade certification and export logistics, which keep out casual entrants but not serious ones.
Key numbers
| ₹ cr | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | 44.9 | 57.1 | 71.2 |
| Revenue growth % | n/a | 27.3 | 24.7 |
| EBITDA | 8.7 | 12.1 | 15.4 |
| EBITDA margin % | 19.4 | 21.1 | 21.6 |
| PAT | 5.1 | 8.0 | 10.2 |
| PAT growth % | n/a | 56.3 | 27.9 |
FY2026 profit grew faster than underlying sales for outside reasons: ocean freight rates collapsed after the Red Sea disruption, saving about ₹2 crore on flat export revenue, while the main raw material more than doubled in price and was absorbed. Both effects are market prices, not management action, and the freight saving lapses as rates normalise.
| Segment, ₹ cr | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Made in-house | 44.4 | 57.1 | 64.1 |
| Made in-house growth % | n/a | 28.8 | 12.2 |
| Bought and resold | 0.5 | 0.0 | 7.1 |
Scorecard
| Block | Rating | Why |
|---|---|---|
| Right to win | MARGINAL | The filing never shows why a buyer picks Shanti over rivals or imports. No patents, no long-term contracts on either side, competition on price by its own account. The real strengths, food-grade certifications and an export network, are undercut by a rejected food-safety registration and a shrinking export book. The one named peer used to prove superior margins turns out to be a misidentified dyes company, so even that comparison fails. |
| Industry and TAM | MARGINAL | The Indian market for these four salts is about ₹470 crore growing 8% a year; the world market about ₹9,600 crore growing 4% (T3). Fine for the company's current size, too small for the expansion being funded. |
| Financial momentum | MARGINAL | Real profits and clean accounting, but FY2026's headline growth was half trading and freight luck, working capital went from zero to 57 days, and promoter pay, project interest and project depreciation will absorb most of current profit before the new plant sells a tonne. |
| Risks, governance, RPTs | MARGINAL | No litigation and no pledges, but the food-safety rejection, two CSR shortfalls, a compliance-by-adjudication record, thin insurance on a hazardous plant, and a pay rise the lenders' covenants required consent for. |
| Promoter and cap table | MARGINAL | Clean share count, no selling, personal guarantees given. Against that: the pre-filing pay reset, the joint managing director simultaneously running a dormant listed company, and a 5% block sold cheaply to an unexplained buyer nine months before outside investors paid five times more. |
| Offer structure | PASS | All fresh money, no exits, one named project, capped general purposes, a monitoring agency. The plan still needs ₹25 crore of future internal cash the current business does not yet generate. |
Watch out for
- The empty plant is the test the expansion has already failed once. Bavla Phase I reached 15% utilisation in eighteen months. The filing never explains the shortfall; late permits explain part of it, demand the rest.
- One buyer in Eswatini is 13.6% of revenue across three years, unnamed. It may be a Coca-Cola concentrate plant or a re-export middleman; the filing does not say (T1).
- An unresolved auditor inconsistency. The filing says the auditor has not changed in three years, while its examination report refers to reliance on "the Previous Auditors". Probably template text, worth a question.
The offer
- Raising about ₹45 to ₹47 crore at the band, all fresh issue, no offer for sale (T1).
- For ₹42.5 crore toward the ₹108 crore Bavla Phase II plant, the rest for general purposes, capped (T1).
- Implied valuation ₹136 to ₹143 crore, from the table above.
- Promoters hold 74.85% before and 50.15% after, selling nothing (T1).
Assessed from the RHP with outside checks on the market, competitors and governance. Numbers carry source tiers: (T1) the filing's audited sections and exchange records, (T3) the issuer-commissioned industry chapter or secondary sources, UNVERIFIED where nothing supports them. Not a recommendation. The valuation section states what the announced band implies and is not a view on whether that price is right.